FineHeart Widens International IP Protection for FlowMaker®
New patents in the United States, China, Japan and India
C. 150 international patents consolidate the company’s position as a pioneer in fully implantable cardiac assist devices.
Synchronization of the mini-pump with the heart and “100% implantable” technology: two major innovations in the treatment of advanced heart failure
BORDEAUX, France–(BUSINESS WIRE)–FineHeart S.A., a clinical stage company developing the ICOMS® device, today announces that it has been granted new patent approvals in the United States, China, Japan, and India. These new patents further strengthen FineHeart’s international intellectual property protection for its cutting-edge FlowMaker® technology, solidifying the company’s position as a leader in fully implantable cardiac assist devices.
The FlowMaker® device is a miniaturized cardiac pump designed to work in harmony with the heart, providing support to patients suffering from advanced heart failure. Its revolutionary “100% implantable” technology sets it apart from traditional cardiac assist devices, offering a more seamless and integrated solution for patients in need of life-saving intervention.
With approximately 150 international patents now in their portfolio, FineHeart is paving the way for a new era in the treatment of heart failure. Their commitment to innovation and dedication to improving patient outcomes have positioned them as a driving force in the field of cardiac assist devices.
By expanding their intellectual property protection to key markets such as the United States, China, Japan, and India, FineHeart is ensuring that their groundbreaking technology remains safeguarded against infringement, while also opening up new opportunities for global collaboration and distribution.
The future looks bright for FineHeart and their FlowMaker® technology, as they continue to push the boundaries of what is possible in the treatment of advanced heart failure.
How will this affect me?
As a consumer, advancements in fully implantable cardiac assist devices like the FlowMaker® technology could potentially offer new hope for individuals suffering from advanced heart failure. The availability of more innovative and integrated treatment options may lead to improved outcomes and quality of life for patients in need of cardiac support.
How will this affect the world?
The expansion of FineHeart’s international intellectual property protection for their FlowMaker® technology has the potential to impact the world by introducing a new standard of care for patients with advanced heart failure. By setting the bar for fully implantable cardiac assist devices, FineHeart is spearheading a global shift towards more effective and patient-centered treatment solutions.
Conclusion
In conclusion, FineHeart’s recent patent approvals mark a significant milestone in the advancement of cardiac assist technology. With their innovative FlowMaker® device leading the way, the future of treating advanced heart failure looks brighter than ever before. As they continue to expand their international intellectual property protection, FineHeart is solidifying their position as a pioneer in the field, offering hope and possibilities for patients around the world.
